Psoriasis (Moderate to Severe) | DecisionBase | US/EU | 2014
What Are the Key Areas of Opportunity for Differentiation According to Dermatologists and Payers?
Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial opportunity. The increasing use of biologics, including the 2012 sales leader, adalimumab (AbbVie/Eisai’s Humira), is driving the growth of the market, but a significant opportunity remains for additional therapies that can offer higher short-term and long-term efficacy as well as lower risk of malignancies and serious infections. The market will become increasingly competitive following the anticipated approval of as many as six therapies (from at least four drug classes). These efficacious agents will significantly raise the bar for psoriasis treatments.
